Ann K Kvam1, Peter Fayers, Finn Wisloff. 1. Department of Haematology, Oslo University Hospital, Ullevaal, Oslo, Norway. a.k.kvam@medisin.uio.no
Abstract
OBJECTIVE: To determine the clinical significance of changes in quality-of-life scores in patients with multiple myeloma (MM), we have estimated the minimal important difference (MID) for the health-related quality-of-life instrument, the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. The MID is the smallest change in a quality-of-life score considered important to patients. METHODS: Between 2006 and 2008, 239 patients with MM completed the EORTC QLQ-C30 at inclusion (T1) and after 3 months (T2). At T2, a structured quality-of-life interview was also performed. MIDs were calculated by using mean score changes (T2-T1) for patients who in the interview stated they had improved, deteriorated or were unchanged. MIDs were also estimated by the receiver-operating characteristic (ROC) curve method as well as by calculation effect sizes using standard deviations of baseline scores. RESULTS: MIDs varied slightly depending on the method used. Patients stating in the interview that they had 'improved' or 'deteriorated' had a corresponding change in EORTC QLQ-C30 score ranging from 6 to15 (improvement) and from 9 to17 (deterioration) (scale range 0-100). The ROC analysis indicated that changes in score from 7 to17 represent clinically important changes to patients. The effect size method suggested 5-6 to be a small and 11-15 to be a medium change. CONCLUSION: Calculation of MIDs as mean score changes or by ROC analysis suggested that a change in the EORTC QLQ-C30 score in the range of approximately 6-17 is considered important by patients with MM. These MIDs are closer to a medium effect size than to a small effect size. Our findings imply that mean score changes smaller than 6 are unlikely to be important to the patients, even if these changes are statistically significant.
OBJECTIVE: To determine the clinical significance of changes in quality-of-life scores in patients with multiple myeloma (MM), we have estimated the minimal important difference (MID) for the health-related quality-of-life instrument, the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. The MID is the smallest change in a quality-of-life score considered important to patients. METHODS: Between 2006 and 2008, 239 patients with MM completed the EORTC QLQ-C30 at inclusion (T1) and after 3 months (T2). At T2, a structured quality-of-life interview was also performed. MIDs were calculated by using mean score changes (T2-T1) for patients who in the interview stated they had improved, deteriorated or were unchanged. MIDs were also estimated by the receiver-operating characteristic (ROC) curve method as well as by calculation effect sizes using standard deviations of baseline scores. RESULTS:MIDs varied slightly depending on the method used. Patients stating in the interview that they had 'improved' or 'deteriorated' had a corresponding change in EORTC QLQ-C30 score ranging from 6 to15 (improvement) and from 9 to17 (deterioration) (scale range 0-100). The ROC analysis indicated that changes in score from 7 to17 represent clinically important changes to patients. The effect size method suggested 5-6 to be a small and 11-15 to be a medium change. CONCLUSION: Calculation of MIDs as mean score changes or by ROC analysis suggested that a change in the EORTC QLQ-C30 score in the range of approximately 6-17 is considered important by patients with MM. These MIDs are closer to a medium effect size than to a small effect size. Our findings imply that mean score changes smaller than 6 are unlikely to be important to the patients, even if these changes are statistically significant.
Authors: Francesco Sparano; Michele Cavo; Pasquale Niscola; Tommaso Caravita; Fabio Efficace Journal: Support Care Cancer Date: 2018-03-20 Impact factor: 3.603
Authors: Michel Delforge; Leonard Minuk; Jean-Claude Eisenmann; Bertrand Arnulf; Letizia Canepa; Alberto Fragasso; Serge Leyvraz; Christian Langer; Yousef Ezaydi; Dan T Vogl; Pilar Giraldo-Castellano; Sung-Soo Yoon; Charles Zarnitsky; Martine Escoffre-Barbe; Bernard Lemieux; Kevin Song; Nizar Jacques Bahlis; Shien Guo; Mara Silva Monzini; Annette Ervin-Haynes; Vanessa Houck; Thierry Facon Journal: Haematologica Date: 2015-03-13 Impact factor: 9.941
Authors: Meletios A Dimopoulos; Michel Delforge; Roman Hájek; Martin Kropff; Maria T Petrucci; Philip Lewis; Annabel Nixon; Jingshan Zhang; Jay Mei; Antonio Palumbo Journal: Haematologica Date: 2012-12-14 Impact factor: 9.941
Authors: Elizabeth K O'Donnell; Jacob P Laubach; Andrew J Yee; Tianqi Chen; Carol Ann Huff; Frank G Basile; Philip M Wade; Claudia E Paba-Prada; Irene M Ghobrial; Robert L Schlossman; Jill N Burke; Cynthia C Harrington; Kathleen J Lively; Hannah F Lyons; Nikhil C Munshi; Kenneth C Anderson; Lorenzo Trippa; Paul G Richardson; Noopur S Raje Journal: Br J Haematol Date: 2018-05-08 Impact factor: 6.998